

Resource Summary Report

Generated by [dkNET](#) on Sep 2, 2026

Cubist Pharmaceuticals

RRID:SCR_003691

Type: Tool

Proper Citation

Cubist Pharmaceuticals (RRID:SCR_003691)

Resource Information

URL: <https://www.merck.com/>

Proper Citation: Cubist Pharmaceuticals (RRID:SCR_003691)

Description: THIS RESOURCE IS NO LONGER IN SERVICE. Documented on April 27th, 2023. Cubist Pharmaceuticals was American biopharmaceutical company that targeted pathogens like MRSA. Company employed 638 people, mostly in Lexington, MA. On 8 December 2014, Merck acquired Cubist.

Abbreviations: Cubist, CBST

Synonyms: Cubist Pharmaceuticals Inc.

Resource Type: commercial organization

Keywords: hospital, acute care, medicine, pharmaceutical, biopharmaceutical, biotherapeutic, antibiotics

Related Condition: Methicillin-resistant Staphylococcus aureus

Availability: THIS RESOURCE IS NO LONGER IN SERVICE

Resource Name: Cubist Pharmaceuticals

Resource ID: SCR_003691

Alternate IDs: ISNI: 0000 0004 0408 8804, grid.417686.a, Wikidata: Q5192265, nlx_158092

Alternate URLs: <https://ror.org/02xwa6p02>

Old URLs: <http://www.cubist.com/>

Record Creation Time: 20220129T080220+0000

Ratings and Alerts

No rating or validation information has been found for Cubist Pharmaceuticals.

No alerts have been found for Cubist Pharmaceuticals.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Karaaslan E, et al. (2026) Confirming ERVEBO Vaccination to Support Ebola Virus Surveillance. *Emerging infectious diseases*, 32(4), 533.

Dolande-Franco M, et al. (2026) Outbreak of *Wickerhamomyces anomalus* (formerly *Candida pelliculosa*) Bloodstream Infections, Venezuela, 2022-20231. *Emerging infectious diseases*, 32(6), 933.

Kruk ME, et al. (2026) Health system use and experience among people with poor mental health: A cross-sectional analysis of the People's Voice Survey in 18 countries. *PLoS medicine*, 23(5), e1004745.

Lin Y, et al. (2026) TiRank prioritizes phenotypic niches in tumor microenvironment for clinical biomarker discovery. *Genome medicine*, 18(1), 23.

Wambua J, et al. (2026) Comparative analysis of the impact of chickenpox and herpes zoster vaccination in Belgium under two different exogenous boosting mechanisms. *PloS one*, 21(3), e0342896.

He M, et al. (2025) Metabolomics and Transcriptomics Reveal the Effects of Different Fermentation Times on Antioxidant Activities of *Ophiocordyceps sinensis*. *Journal of fungi (Basel, Switzerland)*, 11(1).

Goswami R, et al. (2025) Healthcare Worker Attitudes and Perceptions toward Ebola Vaccine, United States, 2024. *Emerging infectious diseases*, 31(12), 2320.

Smesseim I, et al. (2025) Prospective validation of an artificial intelligence assessment in a cohort of applicants seeking financial compensation for asbestosis (PROSBEST). *European radiology experimental*, 9(1), 76.

Burke-Garcia A, et al. (2025) Findings from a qualitative analysis: Social media influencers of color as trusted messengers of HPV vaccination messages. *PloS one*, 20(4), e0319160.

Kortum A, et al. (2025) Evaluation of the accuracy of a low-cost external tocodynamometer in a pilot study in Malawi. PloS one, 20(5), e0323972.

Sooksawasdi Na Ayudhya S, et al. (2025) Attachment Patterns of Avian Influenza H5 Clade 2.3.4.4b Virus in Respiratory Tracts of Marine Mammals, North Atlantic Ocean. Emerging infectious diseases, 31(9), 1729.

Chan MC, et al. (2022) Return of Norovirus and Rotavirus Activity in Winter 2020???21 in City with Strict COVID-19 Control Strategy, China. Emerging infectious diseases, 28(3), 713.

Costales C, et al. (2022) Vaccine-Associated Measles Encephalitis in Immunocompromised Child, California, USA. Emerging infectious diseases, 28(4), 906.

Soeters HM, et al. (2022) CDC's COVID-19 International Vaccine Implementation and Evaluation Program and Lessons from Earlier Vaccine Introductions. Emerging infectious diseases, 28(13), S208.

Page MG, et al. (2006) Anti-MRSA beta-lactams in development. Current opinion in pharmacology, 6(5), 480.